Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
McKesson
Express Scripts
Colorcon
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for XP19986

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug XP19986: Sponsors, patents, clinical trial progress

XP19986 is an investigational drug.

There have been 6 clinical trials for XP19986. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.

The most common disease conditions in clinical trials are Gastroesophageal Reflux, Spinal Cord Injuries, and Muscle Spasticity. The leading clinical trial sponsors are Indivior Inc. and [disabled in preview].

There are nineteen US patents protecting this investigational drug and eighty-two international patents.

Recent Clinical Trials for XP19986
TitleSponsorPhase
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisIndivior Inc.Phase 3
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)Indivior Inc.Phase 2
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back SpasmsIndivior Inc.Phase 2

See all XP19986 clinical trials

Clinical Trial Summary for XP19986

Top disease conditions for XP19986
Top clinical trial sponsors for XP19986

See all XP19986 clinical trials

US Patents for XP19986

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
XP19986   Start Trial Sustained release oral dosage forms of an R-baclofen prodrug XENOPORT, INC. (Santa Clara, CA)   Start Trial
XP19986   Start Trial Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XenoPort, Inc. (Santa Clara, CA)   Start Trial
XP19986   Start Trial Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XenoPort, Inc. (Santa Clara, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Dow
McKinsey
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.